Interferon ß in treatment of COVID-19

Evaluating efficacy and safety of interferone ß-1b (IFN ß-1b) in the treatment of COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100228003449N27

Enrollment

Registered

2020-03-16

Start date

2020-03-15

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia.

Interventions

Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir), patients will receive interferon ß, sub-type 1b (Zist Daru

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with highly suspected or confirmed COVID-19 who are candid for hospitalization and starting triple-drug combination.

Exclusion criteria

Exclusion criteria: History of drug allergy Pregnancy and lactation Uncontrolled baseline diseases including neuropsychiatric disorders, diabetes, thyroid disorders, heart disease, baseline liver failure

Design outcomes

Primary

Measure	Time frame
Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.	—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's record.;Clinical outcome. Timepoint: End of treatment. Method of measurement: Patient's record.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Khalili

Tehran University of Medical Sciences

khalilih@tums.ac.ir+98 21 6695 4715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026